Dominick Colangelo
Chief Executive Officer bei VERICEL CORPORATION
Vermögen: 10 Mio $ am 31.03.2024
Profil
Dominick C.
Colangelo currently works at Vericel Corp., as President, Chief Executive Officer & Director from 2013 and Trevi Therapeutics, Inc., as Independent Director from 2020.
Mr. Colangelo also formerly worked at Promedior, Inc., as President, Chief Executive Officer & Director from 2011 to 2012, Eli Lilly & Co., as Director-Strategy & Business Development, LV Management Group, LLC, as Managing Director, and Oscient Pharmaceuticals Corp., as Executive VP-Corporate Development & Operations from 2005 to 2008.
Mr. Colangelo received his undergraduate degree from State University of New York at Buffalo and graduate degree from Duke University School of Law.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
VERICEL CORPORATION
0,40% | 18.04.2024 | 195 307 ( 0,40% ) | 10 Mio $ | 31.03.2024 |
TREVI THERAPEUTICS, INC.
-.--% | 28.06.2023 | 0 ( -.--% ) | - $ | 31.03.2024 |
Aktive Positionen von Dominick Colangelo
| Unternehmen | Position | Beginn |
|---|---|---|
| VERICEL CORPORATION | Chief Executive Officer | 01.03.2013 |
| TREVI THERAPEUTICS, INC. | Director/Board Member | 29.06.2020 |
Ehemalige bekannte Positionen von Dominick Colangelo
| Unternehmen | Position | Ende |
|---|---|---|
Promedior, Inc.
 Promedior, Inc. Medical SpecialtiesHealth Technology Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA. | Chief Executive Officer | 15.05.2012 |
Oscient Pharmaceuticals Corp.
 Oscient Pharmaceuticals Corp. Miscellaneous Commercial ServicesCommercial Services Oscient Pharmaceuticals Corp. is a biopharmaceutical company that sells and markets products to community-based primary care physicians through its primary care sales force in the United States. It markets two products namely, ANTARA fenofibrate capsules, a cardiovascular product and FACTIVE gemifloxacin mesylate tablets, a fluoroquinolone antibiotic. It also has late-stage antibiotic candidate, Ramoplanin for the treatment of clostridium difficile-associated disease. The company was founded on May 09, 1961 and is headquartered in Waltham, MA. | Chief Operating Officer | 11.12.2008 |
LV Management Group, LLC
 LV Management Group, LLC Investment ManagersFinance Lilly Ventures Management Group LLC (Lilly ventures) is a venture capital firm, a subsidiary of Eli Lilly & Co. founded in 2001 by S.Edward Torres and Ron Laufer. The firm is headquartered in Indianapolis,Indiana. | Chief Investment Officer | 07.12.2005 |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | - |
Ausbildung von Dominick Colangelo
| State University of New York at Buffalo | Undergraduate Degree |
| Duke University School of Law | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| VERICEL CORPORATION | Health Technology |
| TREVI THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Oscient Pharmaceuticals Corp.
Oscient Pharmaceuticals Corp. Miscellaneous Commercial ServicesCommercial Services Oscient Pharmaceuticals Corp. is a biopharmaceutical company that sells and markets products to community-based primary care physicians through its primary care sales force in the United States. It markets two products namely, ANTARA fenofibrate capsules, a cardiovascular product and FACTIVE gemifloxacin mesylate tablets, a fluoroquinolone antibiotic. It also has late-stage antibiotic candidate, Ramoplanin for the treatment of clostridium difficile-associated disease. The company was founded on May 09, 1961 and is headquartered in Waltham, MA. | Commercial Services |
LV Management Group, LLC
LV Management Group, LLC Investment ManagersFinance Lilly Ventures Management Group LLC (Lilly ventures) is a venture capital firm, a subsidiary of Eli Lilly & Co. founded in 2001 by S.Edward Torres and Ron Laufer. The firm is headquartered in Indianapolis,Indiana. | Finance |
Promedior, Inc.
Promedior, Inc. Medical SpecialtiesHealth Technology Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA. | Health Technology |
